参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Feng RM,Zong YN,Cao SM,et al.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun (Lond),2019,39(1):22. [3]Wei JT,Feng Z,Partin AW,et al.Can urinary PCA3 supplement PSA in the early detection of prostate cancer? [J].J Clin Oncol,2014,32(36):4066-4072. [4]Taniguchi K,Karin M.NF-κB, inflammation, immunity and cancer: coming of age[J].Nat Rev Immunol, 2018,18(5):309-324. [5]Pesic M,Greten FR.Inflammation and cancer: tissue regeneration gone awry[J].Curr Opin Cell Biol,2016(43):55-61. [6]Kim HJ,Lee SY,Kim DS,et al.Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy[J].Korean J Intern Med,2020,35(1):171-184. [7]Xue P,Kanai M,Mori Y,et al.Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J].Cancer Med,2014,3(2):406-415. [8]Dolan RD,Laird BJA,Horgan PG,et al.Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review[J].Crit Rev Oncol Hematol,2018(132):130-137. [9]Liu M,Kalbasi A,Beatty GL.Functio Laesa: Cancer Inflammation and Therapeutic Resistance[J].J Oncol Pract,2017,13(3):173-180. [10]Ferrucci PF,Gandini S,Battaglia A,et al.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients[J].Br J Cancer,2015,112(12):1904-1910. [11]Zheng RR,Huang M,Jin C,et al.Cervical cancer systemic inflammation score: a novel predictor of prognosis[J].Oncotarget,2016,7(12):15230-15242. [12]周昳欣,郝吉庆.外周血中性粒细胞与淋巴细胞比值评估小细胞肺癌患者预后的价值[J].中华疾病控制杂志,2017,21(8):827-829. [13]Shimazaki J,Tabuchi T,Nakachi T,et al.Pre-operative granulocyte/lymphocyte ratio as a predictive marker of post-operative complications in patients with colorectal cancer[J].Oncol Lett,2015,9(1):425-429. [14]曾传彪,杨树宏,许方程,等.术前中性粒细胞/淋巴细胞比值与胃癌患者病理特征及其预后的相关性研究[J].解放军预防医学杂志,2017,35(2):156-158. [15]Shen L,Zhang H,Liang L,et al.Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation[J].Radiat Oncol,2014(9):295. [16]Tanaka H,Muguruma K,Toyokawa T,et al.Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage Ⅳ gastric cancer[J].Dig Surg,2014,31(4-5):327-333. [17]Paramanathan A,Saxena A,Morris DL.A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours[J].Surg Oncol,2014,23(1):31-39. [18]Hirahara T,Arigami T,Yanagita S,et al.Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer[J].BMC Cancer,2019,19(1):672. [19]Xue P,Kanai M,Mori Y,et al.Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J].Cancer Med,2014,3(2):406-415. [20]Dalpiaz O,Pichler M,Mannweiler S,et al.Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma[J].Br J Cancer,2014,110(10):2531-2536. [21]Busato WF,Almeida GL,Geraldo J,et al.Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10 ng/ml? [J].Int Braz J Urol,2015,41(2):329-336. [22]Kawahara T,Fukui S,Sakamaki K,et al.Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy[J].Oncotarget,2015,6(31):32169-32176. [23]Maeda Y,Kawahara T,Kumano Y,et al.The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer[J].Urol Int,2016,96(1):123-124. [24]Hashimoto M,Matsumura N,Ohzeki T,et al.The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis[J].Urol Int,2018,101(1):74-79. [25]韩胜利,云志中,李星智,等.中性粒细胞与淋巴细胞比值结合前列腺特异性抗原在前列腺癌早期诊断中的意义[J].中国基层医药,2016,23(19):2894-2897. [26]范润萍,包叶江,张毅敏,等.NLR联合T-PSA检测在前列腺癌诊断中的应用价值[J].中国医师杂志,2018,20(12):1837-1840. [27]马坦途,李庆文,刘贝贝,等.外周血和组织炎性细胞在鉴别PSA4~10 ng/ml的前列腺癌和前列腺增生中的临床意义[J].临床泌尿外科杂志,2019,34(6):434-440. [28]Adhyatma KP,Prapiska FF,Siregar GP,et al.Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio[J].Open Access Maced J Med Sci,2019,7(10):1628-1630. [29]Epstein JI,Egevad L,Amin MB,et al.The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System[J].Am J Surg Pathol,2016,40(2):244-252. [30]林毅锋,姚史武,刘思平.前列腺癌患者中性粒细胞与淋巴细胞比值检测的意义[J].现代泌尿生殖肿瘤杂志,2016,8(4):222-224. [31]Wang H,Gu L,Wu Y,et al.The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤6[J].BMC Cancer,2017,17(1):629. [32]Ferro M,Musi G,Serino A,et al.Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients[J].Urol Int,2019,102(1):43-50. [33]Gokce MI,Hamidi N,Suer E,et al.Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients[J].Can Urol Assoc J,2015,9(11-12):E761-E765. [34]陈昊,何屹,候岩松,等.血清骨性标记物NTx和BALP与前列腺癌骨转移的关系及临床意义[J].临床肿瘤学杂志,2016,21(12):1111-1113. [35]Siddiqui MT,Seydafkan S,Cohen C.GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases[J].Diagn Cytopathol,2014,42(9):809-815. [36]Ozsoy M,Moschini M,Fajkovic H,et al.Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy[J].Prostate Cancer Prostatic Dis,2018,21(1):100-105. [37]武俊平,陈婷婷,宋文华,等.中性粒细胞与淋巴细胞比值对激素抵抗性前列腺癌患者预后的预测价值分析[J].解放军医药杂志,2018,30(4):29-32. [38]van Soest RJ,Templeton AJ,Vera-Badillo FE,et al.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials[J].Ann Oncol,2015,26(4):743-749. [39]亓鸣.PLR和NLR与前列腺癌病理特征的关系及对无去势抵抗生存时间的预测价值[J].中国卫生工程学,2019,18(5):753-755. [40]Kumano Y,Hasegawa Y,Kawahara T,et al.Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide[J].Biomed Res Int,2019(2019):9450838. [41]Nieblas-Toscano D,Arenas-Bonilla AJ,Flores-Martín JF,et al.Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. Papel del índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona[J].Actas Urol Esp,2020,44(3):164-171.
相似文献/References:
[1]袁长翮.超声引导下经直肠前列腺穿刺诊断前列腺癌的价值研究[J].医学信息,2018,31(04):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
YUAN Chang-he.The Value of Ultrasound Guided Transrectal Prostate Puncture in the Diagnosis of Prostate Cancer[J].Medical Information,2018,31(12):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
[2]廖 祺,黄 一,徐 雪.前列腺癌骨转移的疼痛管理[J].医学信息,2018,31(06):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
LIAO Qi,HUANG Yi,XU Xue.Pain Management of Bone Metastasis in Prostate Cancer[J].Medical Information,2018,31(12):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
[3]胡春燕,吴天天,王 殊,等.前列腺癌患者自我感受负担及其影响因素研究[J].医学信息,2018,31(13):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
HU Chun-yan,WU Tian-tian,WANG Shu,et al.Study on Self-perceived Burden and its Influencing Factors in Patients with Prostate Cancer[J].Medical Information,2018,31(12):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
[4]曹志彬,王元天,杨伟忠,等.前列腺健康指数在前列腺癌早期诊断中的价值[J].医学信息,2018,31(23):29.[doi:10.3969/j.issn.1006-1959.2018.23.009]
CAO Zhi-bin,WANG Yuan-tian,YANG Wei-zhong,et al.The Value of Prostate Health Index in Early Diagnosis of Prostate Cancer[J].Medical Information,2018,31(12):29.[doi:10.3969/j.issn.1006-1959.2018.23.009]
[5]张 莹,谢 静.前列腺癌预后标志的研究[J].医学信息,2019,32(09):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
ZHANG Ying,XIE Jing.Prognostic Markers of Prostate Cancer[J].Medical Information,2019,32(12):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
[6]袁也晴,张学齐,汪青蓉,等.KIF14在前列腺癌细胞中的表达及作用[J].医学信息,2019,32(09):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
YUAN Ye-qing,ZHANG Xue-qi,WANG Qing-rong,et al.Expression and Role of KIF14 in Prostate Cancer Cells[J].Medical Information,2019,32(12):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
[7]王 乾,孙 宾,李殷南,等.尿液中肌氨酸、PCA3mRNA在前列腺癌
早期诊断中的应用[J].医学信息,2019,32(14):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
WANG Qian,SUN Bin,LI Yin-nan,et al.Application of Urinary Sarcosine and PCA3mRNA in Early Diagnosis of Prostate Cancer[J].Medical Information,2019,32(12):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
[8]李熹阳,谷明宇,华 琳.影响前列腺癌风险的关键基因识别[J].医学信息,2020,33(02):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]
LI Xi-yang,GU Ming-yu,HUA Lin.Identification of Key Genes Affecting Prostate Cancer Risk[J].Medical Information,2020,33(12):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]
[9]黄 鹏,廖鑫鑫,陆文宝,等.临床评分系统预测前列腺癌根治术后生化复发的研究[J].医学信息,2020,33(08):76.[doi:10.3969/j.issn.1006-1959.2020.08.025]
HUANG Peng,LIAO Xin-xin,LU Wen-bao,et al.Clinical Scoring System Predicts the Value of Biochemical Recurrence after Radical Prostatectomy[J].Medical Information,2020,33(12):76.[doi:10.3969/j.issn.1006-1959.2020.08.025]
[10]贝明龙,缪 瑜.经会阴前列腺12+x针穿刺活检中不同穿刺部位前列腺癌检出率比较[J].医学信息,2021,34(22):88.[doi:10.3969/j.issn.1006-1959.2021.22.026]
BEI Ming-long,MIAO Yu.Comparison of the Detection Rate of Prostate Cancer in Different Puncture Sites in Perineal Prostate 12+x Needle Puncture[J].Medical Information,2021,34(12):88.[doi:10.3969/j.issn.1006-1959.2021.22.026]
[11]陈彦君,刘建萍,龚志勇.预测前列腺癌根治术后生化复发的研究[J].医学信息,2021,34(05):49.[doi:10.3969/j.issn.1006-1959.2021.05.015]
CHEN Yan-jun,LIU Jian-ping,GONG Zhi-yong.Study on the Prediction of Biochemical Recurrence After Radical Prostatectomy[J].Medical Information,2021,34(12):49.[doi:10.3969/j.issn.1006-1959.2021.05.015]